KR102545732B1 - 핵수송 조절인자 및 이의 용도 - Google Patents

핵수송 조절인자 및 이의 용도 Download PDF

Info

Publication number
KR102545732B1
KR102545732B1 KR1020217035649A KR20217035649A KR102545732B1 KR 102545732 B1 KR102545732 B1 KR 102545732B1 KR 1020217035649 A KR1020217035649 A KR 1020217035649A KR 20217035649 A KR20217035649 A KR 20217035649A KR 102545732 B1 KR102545732 B1 KR 102545732B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
trifluoromethyl
bis
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217035649A
Other languages
English (en)
Korean (ko)
Other versions
KR20210137223A (ko
Inventor
에르칸 바로그루
샤론 샤참
딜라라 매컬리
트리나얀 카시압
윌리엄 세나페디스
요제프 란데스만
가리 고란
오리 카리드
샤론 쉑터
Original Assignee
카리오팜 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카리오팜 쎄라퓨틱스, 인코포레이티드 filed Critical 카리오팜 쎄라퓨틱스, 인코포레이티드
Publication of KR20210137223A publication Critical patent/KR20210137223A/ko
Application granted granted Critical
Publication of KR102545732B1 publication Critical patent/KR102545732B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217035649A 2013-06-21 2014-06-20 핵수송 조절인자 및 이의 용도 Active KR102545732B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361838172P 2013-06-21 2013-06-21
US61/838,172 2013-06-21
KR1020167001020A KR102322794B1 (ko) 2013-06-21 2014-06-20 핵수송 조절인자 및 이의 용도
PCT/US2014/043479 WO2014205389A1 (en) 2013-06-21 2014-06-20 Nuclear transport modulators and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167001020A Division KR102322794B1 (ko) 2013-06-21 2014-06-20 핵수송 조절인자 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20210137223A KR20210137223A (ko) 2021-11-17
KR102545732B1 true KR102545732B1 (ko) 2023-06-20

Family

ID=51177201

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217035649A Active KR102545732B1 (ko) 2013-06-21 2014-06-20 핵수송 조절인자 및 이의 용도
KR1020167001020A Active KR102322794B1 (ko) 2013-06-21 2014-06-20 핵수송 조절인자 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167001020A Active KR102322794B1 (ko) 2013-06-21 2014-06-20 핵수송 조절인자 및 이의 용도

Country Status (28)

Country Link
US (5) US9738624B2 (enExample)
EP (2) EP3492455B1 (enExample)
JP (2) JP6730922B2 (enExample)
KR (2) KR102545732B1 (enExample)
CN (3) CN110386919B (enExample)
AU (5) AU2014284168B2 (enExample)
BR (1) BR112015032071B1 (enExample)
CA (1) CA2915365C (enExample)
CY (1) CY1122730T1 (enExample)
DK (2) DK3492455T3 (enExample)
EA (1) EA029743B1 (enExample)
ES (2) ES2724275T3 (enExample)
HR (1) HRP20190524T1 (enExample)
HU (1) HUE042800T2 (enExample)
IL (2) IL243099B (enExample)
LT (1) LT3010892T (enExample)
ME (1) ME03421B (enExample)
MX (1) MX365939B (enExample)
PL (1) PL3010892T3 (enExample)
PT (1) PT3010892T (enExample)
RS (1) RS58581B1 (enExample)
SG (1) SG11201510036TA (enExample)
SI (1) SI3010892T1 (enExample)
SM (1) SMT201900184T1 (enExample)
TR (1) TR201904455T4 (enExample)
UA (1) UA119238C2 (enExample)
WO (1) WO2014205389A1 (enExample)
ZA (1) ZA201509015B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
ES2655645T3 (es) 2011-07-29 2018-02-21 Karyopharm Therapeutics, Inc. Moduladores de transporte nuclear que contienen hidrazida y usos de los mismos
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
PL3404027T3 (pl) 2012-05-09 2020-09-21 Biogen Ma Inc. Modulatory transportu jądrowego i ich zastosowania
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
LT3010892T (lt) 2013-06-21 2019-04-10 Karyopharm Therapeutics Inc. 1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
DK3180331T3 (da) 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
MA43530A (fr) * 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (en) * 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11065230B2 (en) * 2016-09-16 2021-07-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
IL275968B2 (en) 2018-01-10 2024-07-01 Xwpharma Ltd Ketamine prodrugs, preparations containing them and their uses
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
US12318386B2 (en) * 2018-09-07 2025-06-03 Karyopharm Therapeutics Inc. Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
AU2019391942B2 (en) 2018-12-05 2024-03-21 Scohia Pharma, Inc. Macrocyclic compound and use thereof
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
SG11202111993SA (en) 2019-05-01 2021-11-29 Karyopharm Therapeutics Inc Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
WO2021202745A1 (en) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Treatment of covid-19 with a sine compound
CN113880803B (zh) * 2020-07-03 2024-07-02 上海天慈国际药业有限公司 一种xpo-1抑制剂的制备方法
WO2022089629A1 (zh) * 2020-11-02 2022-05-05 江苏柯菲平医药股份有限公司 1,2,4-三氮唑衍生物及其制备方法和用途
CN112294819B (zh) * 2020-12-03 2021-12-14 中国人民解放军军事科学院军事医学研究院 一种炎症小体抑制剂及其应用
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
CN117858873A (zh) 2021-05-20 2024-04-09 卡尔约药物治疗公司 三唑基丙烯酰胺的杂芳基衍生物和结晶形式的合成方法
CN113248474A (zh) * 2021-05-24 2021-08-13 王能能 五元氮唑杂环衍生物及其制备方法和用途
KR20240027792A (ko) 2021-08-13 2024-03-04 엑스더블유파마 리미티드 케타민 유도체의 약제학적 조성물 및 경구 투여 형태
WO2023036217A1 (zh) * 2021-09-08 2023-03-16 南京明德新药研发有限公司 丙烯酰胺类化合物及其应用
IL312179A (en) * 2021-10-29 2024-06-01 Tai Tianqing Pharmaceutical Group Co Ltd Chia Pyridyl-containing compound
WO2023134629A1 (zh) * 2022-01-12 2023-07-20 上海海雁医药科技有限公司 核转运调节剂及其用途
WO2024102477A1 (en) 2022-11-11 2024-05-16 Karyopharm Therapeutics Inc. Crystalline forms of eltanexor and process for preparing same
TWI863768B (zh) * 2023-12-21 2024-11-21 友達光電股份有限公司 顯示裝置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
AU2178497A (en) 1996-04-04 1997-10-29 Shionogi & Co., Ltd. Cephem compounds and drugs containing the compounds
ATE244219T1 (de) 1996-04-25 2003-07-15 Nissan Chemical Ind Ltd Ethylenderivate und pestizide
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
KR20050062645A (ko) 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 신경병증의 예방 또는 치료제
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
AU2005272389B2 (en) 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006088246A1 (ja) 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
ZA200803758B (en) 2005-11-15 2009-08-26 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
US8404726B2 (en) 2006-04-18 2013-03-26 Nippon Chemiphar Co. Ltd. Activating agent for peroxisome proliferator activated receptor δ
US8653115B2 (en) 2006-06-13 2014-02-18 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
PT2090570E (pt) 2006-09-05 2011-12-29 Kyowa Hakko Kirin Co Ltd Derivado de imidazole
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP2124927A2 (en) 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
JP2012532889A (ja) 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
ES2655645T3 (es) 2011-07-29 2018-02-21 Karyopharm Therapeutics, Inc. Moduladores de transporte nuclear que contienen hidrazida y usos de los mismos
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
PL3404027T3 (pl) 2012-05-09 2020-09-21 Biogen Ma Inc. Modulatory transportu jądrowego i ich zastosowania
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
LT3010892T (lt) 2013-06-21 2019-04-10 Karyopharm Therapeutics Inc. 1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015073908A1 (en) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
CN105294681B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
DK3180331T3 (da) 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
ES3001533T3 (en) 2019-12-06 2025-03-05 Bae Systems Plc Light source
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof

Also Published As

Publication number Publication date
KR20160029076A (ko) 2016-03-14
AU2014284168A1 (en) 2015-12-24
IL261612A (en) 2018-10-31
AU2014284168B2 (en) 2018-10-25
CN105339358B (zh) 2019-06-04
US20200199099A1 (en) 2020-06-25
CA2915365A1 (en) 2014-12-24
US11124493B2 (en) 2021-09-21
MX365939B (es) 2019-06-19
CY1122730T1 (el) 2021-03-12
WO2014205389A1 (en) 2014-12-24
US20250059158A1 (en) 2025-02-20
SG11201510036TA (en) 2016-01-28
US20220177445A1 (en) 2022-06-09
CN110183422B (zh) 2023-07-14
JP2020172527A (ja) 2020-10-22
AU2022283662A1 (en) 2023-02-02
US20180155317A1 (en) 2018-06-07
ZA201509015B (en) 2018-07-25
AU2019200147A1 (en) 2019-01-31
WO2014205389A8 (en) 2015-04-02
EP3010892B1 (en) 2018-12-26
JP6730922B2 (ja) 2020-07-29
KR20210137223A (ko) 2021-11-17
CN105339358A (zh) 2016-02-17
LT3010892T (lt) 2019-04-10
TR201904455T4 (tr) 2019-04-22
IL243099A0 (en) 2016-02-01
US9738624B2 (en) 2017-08-22
IL243099B (en) 2020-09-30
DK3492455T3 (da) 2023-08-14
PT3010892T (pt) 2019-04-12
EP3492455A1 (en) 2019-06-05
KR102322794B1 (ko) 2021-11-05
CN110386919A (zh) 2019-10-29
NZ714931A (en) 2021-02-26
MX2015016983A (es) 2016-07-21
ES2724275T3 (es) 2019-09-09
AU2024204818A1 (en) 2024-08-01
BR112015032071A2 (pt) 2017-07-25
BR112015032071B1 (pt) 2022-06-14
AU2020277088A1 (en) 2020-12-24
JP7061161B2 (ja) 2022-04-27
CN110183422A (zh) 2019-08-30
EP3010892B8 (en) 2019-05-22
EA029743B1 (ru) 2018-05-31
CN110386919B (zh) 2023-07-14
EP3010892A1 (en) 2016-04-27
US20160152596A1 (en) 2016-06-02
EA201690044A1 (ru) 2016-05-31
RS58581B1 (sr) 2019-05-31
HK1223936A1 (en) 2017-08-11
DK3010892T3 (en) 2019-04-15
AU2020277088B2 (en) 2022-09-08
SMT201900184T1 (it) 2019-05-10
US11945794B2 (en) 2024-04-02
CA2915365C (en) 2022-08-16
SI3010892T1 (sl) 2019-05-31
ME03421B (me) 2020-01-20
JP2016522266A (ja) 2016-07-28
HRP20190524T1 (hr) 2019-05-17
HUE042800T2 (hu) 2019-07-29
PL3010892T3 (pl) 2019-07-31
EP3492455B1 (en) 2023-05-17
ES2952774T3 (es) 2023-11-06
US10407405B2 (en) 2019-09-10
UA119238C2 (uk) 2019-05-27

Similar Documents

Publication Publication Date Title
KR102545732B1 (ko) 핵수송 조절인자 및 이의 용도
US10709706B2 (en) Nuclear transport modulators and uses thereof
WO2017117529A1 (en) Nuclear transport modulators and uses thereof
HK40009479A (en) 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
HK1223936B (en) 1,2,4-triazoles as nuclear transport modulators and uses thereof
NZ714931B2 (en) Nuclear transport modulators and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211101

Application number text: 1020167001020

Filing date: 20160114

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211102

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220110

Patent event code: PE09021S01D

PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220922

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230315

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration